ACADIA Pharmaceuticals Inc.

ACAD

Held by 12 specialist biotech funds

High Convergence

12 funds opened new positions. Next phase3 readout (Carbetocin): Oct 2025. Short interest: 10.3% of float.

BiotechnologyCEO: Catherine E. Owen AdamsIPO: 2004Website ↗

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Recent News & Research

PubMed

Retraction statement: Carbetocin versus syntometrine for prevention of postpartum hemorrhage after cesarean section.

# Summary for ACADIA Investors This article is a **retraction notice unrelated to ACADIA's pipeline** — it concerns obstetric medications (carbetocin and syntometrine) for preventing postpartum hemorrhage, with no connection to ACADIA's focus areas (psychiatry, neurology, and rare diseases). **Why this doesn't matter for ACADIA investors:** This retracted study has no bearing on ACADIA's clinical programs, competitive landscape, or commercial prospects. Investors should disregard this reference unless tracking it for academic integrity concerns in the broader medical literature.

Dec 1, 2026

PubMed

Retrospective cost-effectiveness analysis of carbetocin for the prevention of postpartum hemorrhage after vaginal birth: Evidence from a tertiary maternity center in France.

# Investment Summary This retrospective French cost-effectiveness study evaluates carbetocin for postpartum hemorrhage (PPH) prevention following vaginal delivery—a standard-of-care application outside ACADIA's pipeline focus. The analysis is clinically relevant to obstetrics but has no direct bearing on ACADIA's marketed portfolio (Nuplazid for Parkinson's psychosis, Fanapt for schizophrenia) or pipeline assets, which concentrate on CNS disorders. **Why it doesn't matter for ACAD investors:** ACADIA has no involvement in carbetocin or obstetric indications; this study provides no visibility into company-specific clinical efficacy, market expansion, or competitive positioning.

May 4, 2026

PubMed

Carbetocin - a long-acting oxytocin analogue - increases the blood supply to the reproductive tract of rams.

# Research Summary for ACAD Investors This preclinical study demonstrates that carbetocin, a long-acting oxytocin analogue, enhances vascular perfusion to reproductive tissues in animal models—a mechanism potentially relevant to sexual dysfunction or reproductive disorders in humans. While ACAD's current pipeline focuses on psychiatric and neurological indications, positive vascular outcomes could support future development in sexual health or fertility applications if the company pursues this therapeutic area. The findings remain preliminary (animal data only) and lack direct connection to ACAD's marketed products, limiting immediate commercial impact on near-term revenue.

Apr 1, 2026

PubMed

One dose, big impact: Revisiting carbetocin in high-risk polyhydramnios deliveries.

I appreciate the request, but I need to clarify that I cannot access or verify the content of articles published in April 2026, as that is a future date beyond my knowledge cutoff (April 2024). Additionally, I'm not aware of carbetocin being a clinical-stage or marketed product for ACADIA Pharmaceuticals—ACAD's portfolio primarily focuses on CNS disorders (pimavanserin, trofinetide, etc.). To provide an accurate investment summary, I would need: 1. Confirmation the article actually exists and its correct publication details 2. Verification of ACAD's involvement or IP position in carbetocin 3. The actual article text to assess clinical/commercial relevance If you have access to the full article or can verify these details, I'm happy to provide a targeted analysis for biotech investors.

Apr 1, 2026

ACADIA Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research